Viridian director granted 32,341 stock options
Viridian Therapeutics director Jennifer K. Moses received a grant of stock options covering 32,341 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Viridian Therapeutics director Jennifer K. Moses received a grant of stock options covering 32,341 shares of common stock. The options have an exercise price of $18.48 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she holds 32,341 stock options directly according to this filing.
Insider Trade Summary
Grant/Award: 32,341 shares
Grant/Award
1 txn
Insider
Moses Jennifer K.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,341 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,341 contracts (Direct)
Footnotes (1)
- F1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Key Figures
Options granted: 32,341 options
Exercise price: $18.48 per share
Expiration date: July 1, 2036
+2 more
5 metrics
Options granted
32,341 options
Stock Option (Right to Buy) grant
Exercise price
$18.48 per share
Exercise price of stock options
Expiration date
July 1, 2036
Option expiration
Post-grant option holdings
32,341 options
Total shares following transaction
Vesting trigger date
July 1, 2027
Full vesting or 2027 annual meeting
Key Terms
Stock Option (Right to Buy), derivative security, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_type: "derivative" for the option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: "18.4800" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-07-01T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The option vests in full upon the earlier to occur of (i) July 1, 2027..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Viridian Therapeutics (VRDN) director Jennifer K. Moses report in this Form 4?
Jennifer K. Moses reported receiving a grant of stock options for 32,341 shares of Viridian Therapeutics common stock. These options are a compensation award, not an open-market stock purchase or sale, and are documented as a derivative security in this insider transaction filing.
What is the exercise price of the Viridian Therapeutics options granted to Jennifer K. Moses?
The stock options granted to Jennifer K. Moses have an exercise price of $18.48 per share. This means she can buy Viridian Therapeutics common stock at $18.48 once the options vest, regardless of the market price at that time, subject to the award’s terms.
When do Jennifer K. Moses’s Viridian Therapeutics options vest according to the Form 4?
The option vests in full on the earlier of July 1, 2027 or Viridian Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on her continued service on the company’s board of directors through that applicable vesting date, as described in the footnote.
How many Viridian Therapeutics options does Jennifer K. Moses hold after this reported grant?
After this grant, Jennifer K. Moses is reported as holding 32,341 stock options directly. The Form 4 shows “total shares following transaction” of 32,341 for this derivative security, indicating her post-transaction option position from this specific award.
Is the Viridian Therapeutics Form 4 for a stock purchase or a compensation award?
The Form 4 reflects a compensation-related stock option award, not an open-market stock purchase. The transaction code is “A” for grant, and the options carry a zero-dollar transaction price with a specified exercise price of $18.48 per share, expiring in 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
